I will discuss the use of genomics and data science in drug discovery at GSK, and particularly in the selection and validation of drug targets. I’ll highlight the interplay between experimental science and informatics, and will discuss recently published work highlighting the value of genetic information in selecting drug targets/indications. Motivated by this, I will also include a sketch of work ongoing and planned in this area at GSK, particularly with respect to the potential to integrate electronic health record and genomics information. I will also describe work at Open Targets (www.targetvalidation.org), including both experimental and informatics aspects. I will focus on the key concepts and avoid technical detail, both regarding genomics and data science.